Previous Article | Next Article 
Journal of Virology, September 2006, p. 9259-9269, Vol. 80, No. 18
0022-538X/06/$08.00+0 doi:10.1128/JVI.00888-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation
Craig Pace,1
Jean Keller,1
David Nolan,1
Ian James,1
Silvana Gaudieri,1,2
Corey Moore,1 and
Simon Mallal1,3*
Centre for Clinical Immunology & Biomedical Statistics, Royal Perth Hospital & Murdoch University, GPO Box X2213, Perth 6847, Australia,1
Centre for Forensic Science, School of Anatomy & Human Biology, University of Western Australia, Nedlands, Australia,2
Department of Clinical Immunology & Biochemical Genetics, Royal Perth Hospital, Wellington St., Perth 6000, Australia3
Received 2 May 2006/
Accepted 14 June 2006
APOBEC3G and APOBEC3F restrict human immunodeficiency virus type 1 (HIV-1) replication in vitro through the induction of G
A hypermutation; however, the relevance of this host antiviral strategy to clinical HIV-1 is currently not known. Here, we describe a population level analysis of HIV-1 hypermutation in near-full-length clade B proviral DNA sequences (n = 127). G
A hypermutation conforming to expected APOBEC3G polynucleotide sequence preferences was inferred in 9.4% (n = 12) of the HIV-1 sequences, with a further 2.4% (n = 3) conforming to APOBEC3F, and was independently associated with reduced pretreatment viremia (reduction of 0.7 log10 copies/ml; P = 0.001). Defective vif was strongly associated with HIV-1 hypermutation, with additional evidence for a contribution of vif amino acid polymorphism at residues important for APOBEC3G-vif interactions. A concurrent analysis of APOBEC3G polymorphism revealed this gene to be highly conserved at the amino acid level, although an intronic allele (6,892 C) was marginally associated with HIV-1 hypermutation. These data indicate that APOBEC3G-induced HIV-1 hypermutation represents a potent host antiviral factor in vivo and that the APOBEC3G-vif interaction may represent a valuable therapeutic target.
* Corresponding author. Mailing address: Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth 6000, Western Australia. Phone: 61 89 224 2899. Fax: 61 89 224 2920. E-mail:
s.mallal{at}murdoch.edu.au.
Supplemental material for this article may be found at http://jvi.asm.org/.
Journal of Virology, September 2006, p. 9259-9269, Vol. 80, No. 18
0022-538X/06/$08.00+0 doi:10.1128/JVI.00888-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Koning, F. A., Newman, E. N. C., Kim, E.-Y., Kunstman, K. J., Wolinsky, S. M., Malim, M. H.
(2009). Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets. J. Virol.
83: 9474-9485
[Abstract]
[Full Text]
-
Piantadosi, A., Humes, D., Chohan, B., McClelland, R. S., Overbaugh, J.
(2009). Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif. J. Virol.
83: 7805-7814
[Abstract]
[Full Text]
-
Henriet, S., Mercenne, G., Bernacchi, S., Paillart, J.-C., Marquet, R.
(2009). Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors. Microbiol. Mol. Biol. Rev.
73: 211-232
[Abstract]
[Full Text]
-
Malim, M. H
(2009). APOBEC proteins and intrinsic resistance to HIV-1 infection. Phil Trans R Soc B
364: 675-687
[Abstract]
[Full Text]
-
Armitage, A. E., Katzourakis, A., de Oliveira, T., Welch, J. J., Belshaw, R., Bishop, K. N., Kramer, B., McMichael, A. J., Rambaut, A., Iversen, A. K. N.
(2008). Conserved Footprints of APOBEC3G on Hypermutated Human Immunodeficiency Virus Type 1 and Human Endogenous Retrovirus HERV-K(HML2) Sequences. J. Virol.
82: 8743-8761
[Abstract]
[Full Text]
-
Land, A. M., Ball, T. B., Luo, M., Pilon, R., Sandstrom, P., Embree, J. E., Wachihi, C., Kimani, J., Plummer, F. A.
(2008). Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya. J. Virol.
82: 8172-8182
[Abstract]
[Full Text]
-
Mulder, L. C. F., Harari, A., Simon, V.
(2008). Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. USA
105: 5501-5506
[Abstract]
[Full Text]
-
Munk, C., Zielonka, J., Constabel, H., Kloke, B.-P., Rengstl, B., Battenberg, M., Bonci, F., Pistello, M., Lochelt, M., Cichutek, K.
(2007). Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells. J. Virol.
81: 7048-7060
[Abstract]
[Full Text]
-
Gallois-Montbrun, S., Kramer, B., Swanson, C. M., Byers, H., Lynham, S., Ward, M., Malim, M. H.
(2007). Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress Granules. J. Virol.
81: 2165-2178
[Abstract]
[Full Text]